Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
Detailed price information for Artelo Biosciences Inc (ARTL-Q) from The Globe and Mail including charting and trades.
Nasdaq6d
Artelo Biosciences announces acceptance of ART26.12 into NIH PSPP program
PSPP. The HEAL Initiative is an NIH-wide effort to accelerate scientific solutions to the overdose epidemic, including opioid and stimulant use disorders, and the crisis of pain. Launched in April ...
Business Wire2d
CUPE Alberta Responds to Continued Alberta Government Interference in Public Sector Pension Plans
The Government of Alberta’s unilateral changes to AIMCo’s board without any consultation with public sector unions representing members in the Local A ...
Business Wire1mon
PsychoGenics Awarded an NIH Contract to Test and Identify Novel Therapeutics for Pain
This contract is part of the NIH HEAL Initiative Preclinical Screening Platform for Pain (PSPP). “There is a tremendous need for treatments that mitigate the risks associated with opioid use for ...
Artelo Biosciences announces acceptance of ART26.12 into NIH PSPP program
Artelo Biosciences (ARTL) announced that ART26.12, the Company’s lead clinical FABP inhibitor, has been accepted into the NIH Helping to ...